Browse All

Current Filters

CLEAR FILTER x

TITLE

Conversion Rate of Essential Tremor to Essential Tremor-Parkinson’s Disease: Data from a Prospective, Longitudinal Study

Genotype-Phenotype correlation in Parkin-Parkinson’s disease

Author:Jayadev Menon, Poornima   Sambin, Sara   Criniere-Boizet, Baptiste   Courtin, Thomas   Casse, Fanny   Tesson, Christelle   Ferrien, Melanie   Flamand-Roze, Emmanuel   Lejeune, Francois-Xavier   Lanore, Aymeric   Mangone, Graziella   Mariani, Louise-Laure   Aasly, Jan   Gan Or, Ziv   Yu, Eric   Dauvilliers, Yves   Zimprich, Alexander   Alvarez Fernandez, Ignacio   Pastor, Pau   Di Fonzo, Alessio   Bhatia, Khailash   Magrinelli, Francesca   Houlden, Henry   Real, Raquel   Narendra, Derek   Lin, Hsin-Pin   Jovanovic, Carna   Koks, Sulev   Lynch, Timothy   Gallagher, Amy   Vandenberghe, Wim   Gasser, Thomas   Morris, Huw   Klein, Christine   Brockmann, Kathrin   Corti, Olga   Brice, Alexis   Lesage, Suzanne   Corvol, Jean-Christophe   

Session Name:P3: Movement Disorders: Biomarkers and Genetics of Parkinson's Disease 1  

Topic:Movement Disorders  

Program Number:P3.012  

Author Institution:ICM/ Paris Brain Institute, Paris, France  NTNU, Trondheim, Norway  Mcgill University, Montreal, QC, Canada  Montpellier, Montpellier, France  Medizinische Universität Wien, Vienna, Austria  University Mutua de Terrassa, Terrassa, Spain  University of Milan, Milan, Italy  UCL, London, United Kingdom  NIH, Bethesda, MD  University of Belgrade, Belgrade, Serbia  University of Perron, Perth, Australia  Dublin Neurological Institute, Dublin, Ireland  University of Leuven, Leuven, Belgium  University of Tuebingen, Tuebingen, Germany  University of Luebeck, Luebeck, Germany  

Infusion-Related Reactions With Ocrelizumab: Risk Factors, Symptom Management and Patient Choices in the ENSEMBLE PLUS Study

Author:Bermel, Robert   Killestein, Joep   Berger, Thomas   Brochet, Bruno   Carroll, William   Freedman, Mark   Holmoy, Trygve   Karabudak, Rana   Nos, Carlos   Patti, Francesco   Perrin Ross, Amy   Vanopdenbosch, Ludo   Vollmer, Timothy   Buffels, Regine   Kadner, Karen   Bortolami, Oscar   Hartung, Hans-Peter   

Session Name:P7: MS Therapeutics 1  

Topic:MS and Inflammatory Disease  

Program Number:P7.003  

Author Institution:Mellen Center for MS, Department of Neurology, Cleveland Clinic, Cleveland, OH, USA, Cleveland, OH  Department of Neurology, VU University Medical Centre, Amsterdam, The Netherlands, Amsterdam, Netherlands  Department of Neurology, Medical University of Vienna, Vienna, Austria, Vienna, Austria  University of Bordeaux, Bordeaux, France, Bordeaux, France  Department of Neurology, Sir Charles Gairdner Hospital, Perron Institute for Neurological and Translational Science, The University of Western Australia, Nedlands, Australia, Subiaco, Australia  University of Ottawa, Department of Medicine and the Ottawa Hospital Research Institute, Ottawa, ON, Canada, Ottawa, ON, Canada  Department of Neurology, Akershus University Hospital, Lørenskog, Norway, Lasker, Norway  Department of Neurology, Hacettepe University Faculty of Medicine, Ankara, Turkey, Ankara, Turkey  Centre d’Esclerosi Mútiple de Catalunya (Cemcat), Vall d’Hebron Hospital Universitari, Barcelona, Spain, Barcelona, Spain  Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, Neuroscience Section and Multiple Sclerosis Centre, University of Catania PO Policlinico G Rodolico, Catania, Italy, Catania, Italy  Loyola University Chicago, Chicago, IL, USA , Oak Brook, IL  Department of Neurology, AZ Sint-Jan Brugge-Oostende, Brugge, Belgium, Brugge, Belgium  Department of Neurology, University of Colorado School of Medicine, Aurora, CO, USA, Aurora, CO  F. Hoffmann-La Roche Ltd, Basel, Switzerland, Toulon, France  F. Hoffmann-La Roche Ltd, Basel, Switzerland, Basel, Switzerland  Department of Neurology, UKD, Centre of Neurology and Neuropsychiatry and LVR-Klinikum, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany, Dusseldorf, Germany